Literature DB >> 9624062

Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study.

R Mahadeva1, K Webb, R C Westerbeek, N R Carroll, M E Dodd, D Bilton, D A Lomas.   

Abstract

OBJECTIVES: To assess the effect on clinical outcome of managing paediatric and adult patients with cystic fibrosis at specialised cystic fibrosis centres.
DESIGN: Cross sectional study.
SETTING: Two adult cystic fibrosis centres in the United Kingdom.
SUBJECTS: Patients from an adult cystic fibrosis centre in Manchester were subdivided into those who had received continuous care from paediatric and adult cystic fibrosis centres (group A), and those who had received paediatric care in a centre not specialising in cystic fibrosis followed by adult care in a cystic fibrosis centre (group B). Group C were referrals to the new adult cystic fibrosis centre in Cambridge who had received neither paediatric nor adult centre care for their cystic fibrosis. MAIN OUTCOME MEASURES: Body mass index (weight (kg)/height (m2)), lung function (forced expiratory volume in one second (FEV1 percentage of predicted)), the Northern chest x ray film score, and age at colonisation with Pseudomonas aeruginosa.
RESULTS: A prominent stepwise increase in body mass index was associated with increasing amounts of care at a cystic fibrosis centre; 18.3, 20.2, and 21.3 for groups C, B, and A respectively (P<0.001). Improved nutritional status was correlated with a higher FEV1 and better (lower) chest x ray film scores; r=0. 52 and -0.45 respectively (P<0.001 for both).
CONCLUSION: These findings provide the first direct evidence that management of cystic fibrosis in paediatric and adult cystic fibrosis centres results in a better clinical outcome, and strongly supports the provision of these specialist services.

Entities:  

Mesh:

Year:  1998        PMID: 9624062      PMCID: PMC28574          DOI: 10.1136/bmj.316.7147.1771

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  23 in total

1.  Influence of respiratory exacerbations on lung function variables and nutritional status in CF patients.

Authors:  H J Neijens; E J Duiverman; K F Kerrebijn; M Sinaasappel
Journal:  Acta Paediatr Scand Suppl       Date:  1985

2.  Cystic fibrosis mortality in England and Wales and in Victoria, Australia 1976-80.

Authors:  P Phelan; E Hey
Journal:  Arch Dis Child       Date:  1984-01       Impact factor: 3.791

3.  Incidence and risk of cross-colonization in cystic fibrosis holiday camps.

Authors:  J A Hoogkamp-Korstanje; J van der Laag
Journal:  Antonie Van Leeuwenhoek       Date:  1980       Impact factor: 2.271

4.  Communicability of Pseudomonas aeruginosa in a cystic fibrosis summer camp.

Authors:  D P Speert; D Lawton; S Damm
Journal:  J Pediatr       Date:  1982-08       Impact factor: 4.406

5.  Relative underweight in cystic fibrosis and its prognostic value.

Authors:  R Kraemer; A Rüdeberg; B Hadorn; E Rossi
Journal:  Acta Paediatr Scand       Date:  1978-01

6.  A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto.

Authors:  M Corey; F J McLaughlin; M Williams; H Levison
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

7.  Alpha1-antitrypsin deficiency alleles and the Taq-I G-->A allele in cystic fibrosis lung disease.

Authors:  R Mahadeva; R C Westerbeek; D J Perry; J U Lovegrove; D B Whitehouse; N R Carroll; R I Ross-Russell; A K Webb; D Bilton; D A Lomas
Journal:  Eur Respir J       Date:  1998-04       Impact factor: 16.671

8.  Hospital epidemiology of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  D P Speert; M E Campbell
Journal:  J Hosp Infect       Date:  1987-01       Impact factor: 3.926

9.  Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin and placebo therapy.

Authors:  R Wientzen; C B Prestidge; R I Kramer; G H McCracken; J D Nelson
Journal:  Am J Dis Child       Date:  1980-12

10.  Pseudomonas aeruginosa isolates: comparisons of isolates from campers and from sibling pairs with cystic fibrosis.

Authors:  M J Thomassen; C A Demko; C F Doershuk; J M Root
Journal:  Pediatr Pulmonol       Date:  1985 Jan-Feb
View more
  49 in total

1.  Normal growth in cystic fibrosis associated with a specialised centre.

Authors:  C E Collins; L MacDonald-Wicks; S Rowe; E V O'Loughlin; R L Henry
Journal:  Arch Dis Child       Date:  1999-09       Impact factor: 3.791

Review 2.  Cystic fibrosis.

Authors:  P Robinson
Journal:  Thorax       Date:  2001-03       Impact factor: 9.139

Review 3.  Infection control in cystic fibrosis: methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and the Burkholderia cepacia complex.

Authors:  J R Govan
Journal:  J R Soc Med       Date:  2000       Impact factor: 5.344

Review 4.  Prospects for gene therapy in cystic fibrosis.

Authors:  A Jaffé; A Bush; D M Geddes; E W Alton
Journal:  Arch Dis Child       Date:  1999-03       Impact factor: 3.791

5.  Managed clinical networks.

Authors:  S Cropper; A Hopper; S A Spencer
Journal:  Arch Dis Child       Date:  2002-07       Impact factor: 3.791

Review 6.  Recent advances in cross-infection in cystic fibrosis: Burkholderia cepacia complex, Pseudomonas aeruginosa, MRSA and Pandoraea spp.

Authors:  Andrew M Jones; A Kevin Webb
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

Review 7.  National Health Services for patients with cystic fibrosis: the good, the bad and the ugly.

Authors:  Sarah Walters
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

8.  Exercise and sport in cystic fibrosis: benefits and risks.

Authors:  A K Webb; M E Dodd
Journal:  Br J Sports Med       Date:  1999-04       Impact factor: 13.800

Review 9.  Shared care--is it worth it for the patient?

Authors:  Iolo Doull
Journal:  J R Soc Med       Date:  2012-06       Impact factor: 5.344

10.  Development of a modern adult cystic fibrosis centre in Manchester.

Authors:  A Kevin Webb; Roy Dudley-Southern; Andrew M Jones
Journal:  J R Soc Med       Date:  2010-07       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.